Category Archives: News
RECENT APPROACHES FOR SMOKING CESSATION IN CROHN’S DISEASE: A QUALITATIVE REVIEW
The clinical practice guideline for Crohn’s disease (CD) management strongly recommends the avoidance and cessation of smoking. However, no standardized smoking cessation (SC) program exists for CD patients. Results from a nationwide survey among U.S. … Continue reading
REGULATION OF HUMAN INTESTINAL ORGANOID REACTIVE OXYGEN SPECIES PRODUCTION AND MITOCHONDRIAL FUNCTION BY DUOX2 GENETIC VARIATION AND MICROBIAL PRODUCTS
The DUOX2 intestinal epithelial NADPH oxidase is upregulated in Crohn’s Disease (CD), and DUOX2 mutations are associated with increased CD risk. Oxidative stress and loss of mitochondrial function disrupt the intestinal barrier promoting inflammatory r… Continue reading
UNIQUE GENE EXPRESSION IN GUT-DERIVED PHAGOCYTIC IMMUNE CELLS FROM IBD PATIENTS
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), have a complex immunopathogenesis involving chronic, dysregulated inflammation of the gut in response to commensal microbes. Current therapies, such as Anti-… Continue reading
RISK OF ANAL CANCER IN INFLAMMATORY BOWEL DISEASE PATIENTS IN THE US: A POPULATION-BASED STUDY 2008–2018
Patients with inflammatory bowel disease (IBD) are at elevated risk of developing anal cancer. However, it remains unclear whether the increased risk manifests from immunosuppressant use or location of the disease (inflammation). We aimed to examine wh… Continue reading
STOCHASTIC INTERINDIVIDUAL MICROBIOME VARIATION MAY GUIDE PROTECTIVE PERINATAL PROBIOTIC DEVELOPMENT AGAINST IBD
The purpose of our experiment was to explore how stochastic inter-individual variation in the mammalian gut microbiome may link to inflammatory bowel disease (IBD) susceptibility, and guide the development of a perinatal preventative probiotic. Continue reading
MUC1-C IS A DRUGGABLE TARGET FOR TREATMENT OF COLITIS AND PROGRESSION OF COLITIS-ASSOCIATED COLORECTAL CANCER
The MUC1-C oncoprotein evolved in mammals to protect epithelial cells, such as those lining the gastrointestinal tract, from loss of homeostasis. In this way, MUC1-C activates pathways that contribute to inflammation, proliferation and remodeling assoc… Continue reading
NANOPARTICLE-ENCAPSULATED BROMODOMAIN-CONTAINING PROTEIN 4 INHIBITORS FOR THERAPEUTICS OF INFLAMMATORY BOWEL DISEASE
Ulcerative Colitis (UC) and Crohn’s disease (CD), the two major types of inflammatory bowel disease (IBD), are chronic diseases with recurrent symptoms and significant morbidity. Long-term persistence of chronic inflammation in IBD is among the major f… Continue reading
SER-287, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC FOR PATIENTS WITH ACTIVE MILD-TO-MODERATE ULCERATIVE COLITIS, PRODUCES REMISSION ASSOCIATED METABOLITES, REDUCES INTESTINAL EPITHELIAL IL-8 SECRETION AND PROTECTS EPITHELIAL BARRIER FUNCTION IN VITRO
In a Phase 1b study of mild-to-moderate ulcerative colitis (UC) (Henn et al. Gastro 2020), oral daily dosing of SER-287, a purified consortium of Firmicutes spores administered after vancomycin pre-conditioning, led to significantly higher rates of cli… Continue reading
THE CLINICAL FEATURES AND PROGNOSTIC VALUE OF INFLAMMATORY POLYPS IN THE J POUCH OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED BY PROCTOCOLECTOMY WITH ILEAL POUCH-ANAL ANASTOMOSIS
Patients with inflammatory bowel disease (IBD) sometimes require proctocolectomy with ileal pouch-anal anastomosis (IPAA) due to medically refractory colitis or neoplasia. However, pouchitis can develop in up to 80% of patients after the surgery. Given… Continue reading
CHARACTERIZATION OF IMMUNE PHENOTYPES AS PREDICTIVE BIOMARKERS FOR RESPONSE TO THE α4β7 INTEGRIN BLOCKER, VEDOLIZUMAB
The etiology of inflammatory bowel disease (IBD) is unknown. However, chronic inflammation from T cell activation and its subsequent tissue damage is implicated in the pathogenesis of IBD. Vedolizumab (VDZ), a monoclonal antibody against α4β7 integrin … Continue reading